Oral cancer detection is changing quickly, and dental hygienists are finding themselves at the center of one of the biggest shifts in preventive care we’ve seen in years. 

For decades, oral cancer screenings have relied heavily on what we can see, feel, document, and monitor. Visual examination, tactile palpation, patient history, risk assessment, and biopsy referral when something appears suspicious have long been the foundation of oral cancer detection. They are not going away, and they should not. 

But in 2026, we are beginning to move beyond simply looking at tissue and waiting for visible changes before taking the next step. That matters because one of the most common challenges in managing oral lesions has always been uncertainty. How many times have we heard some version of “Let’s watch it” or, “Let’s reevaluate in two weeks.” 

In many cases, monitoring is appropriate. Not every ulceration, tissue change, or irritation requires immediate escalation. Dentistry has always required clinical judgment, but we also know the uncomfortable side of “wait and see.” That is where salivary insights and genomic technology are beginning to shift the conversation. 

What we’ve traditionally relied on 

Oral cancer detection has historically depended on routine visual and tactile examinations. A comprehensive screening includes evaluation of the lips, tongue, floor of the mouth, palate, buccal mucosa, oropharynx, and lymphatic regions of the head and neck. Clinicians assess for ulcerations, leukoplakia, erythroplakia, induration, tissue fixation, unexplained bleeding, asymmetry, and changes in tissue color or texture.¹ 

Adjunctive screening tools have also been introduced over the years. Tissue fluorescence, toluidine blue, brush biopsy, and earlier salivary biomarker testing have all attempted to support earlier detection and better referral decisions.² Some of these tools have helped clinicians gather more information, but limitations remain around specificity, sensitivity, workflow integration, and the ability to detect molecular changes before clinical signs become obvious. 

Saliva itself has been studied for years as a diagnostic medium. Researchers have evaluated inflammatory cytokines, messenger RNA, proteins, metabolites, microbial patterns, and other biomarkers associated with oral squamous cell carcinoma.³ Inflammatory biomarkers such as IL-6 and IL-8 have been linked to oral cancer progression, while shifts in the oral microbiome have also shown associations with malignancy and chronic inflammatory environments.^4,5 

This is where salivary insights and oral-systemic care begin to overlap in a much more meaningful way. Oral cancer risk is not isolated from the rest of the body. Tobacco use, alcohol consumption, HPV exposure, chronic inflammation, immune dysregulation, periodontal disease, and microbiome disruption can all influence disease pathways. As our understanding of these connections grows, saliva is becoming more than a sample. It is becoming a window into risk, inflammation, host response, and early biological change. 

And we have all had the patient who delays follow-up because the lesion does not hurt. We have all had the patient who thinks, “If it was serious, I would feel it.” We have all had the lesion that looked nonspecific, small, or clinically ambiguous, yet still raised concern. That is exactly why dentistry is beginning to move toward technologies that may help evaluate what is happening beneath the surface, before visible progression becomes the only trigger for action. 

What’s new in oral cancer detection technology 

One of the most significant developments emerging in dentistry is the use of next-generation sequencing to identify cancer-associated somatic mutations shed directly from oral lesions into saliva. 

This represents a major evolution from earlier salivary testing methods that focused primarily on broad inflammatory or microbial biomarkers. Newer genomic screening technologies can analyze DNA mutation patterns associated with precancerous and cancerous lesions. In other words, clinicians are no longer limited only to what they can see clinically or what general inflammation may suggest. We are entering a phase where molecular-level information may help support clinical decision-making. 

The workflow is intentionally designed to fit within the dental setting. A patient completes a saline rinse during a preventive appointment. The sample is then analyzed using advanced sequencing technology capable of detecting mutation patterns associated with oral squamous cell carcinoma and dysplastic lesions. Results can be delivered digitally within days and may help support referral decisions, lesion triage, follow-up recommendations, and patient conversations. 

To be clear, this technology is not replacing the visual exam, clinical judgment, or biopsy. The biopsy remains the diagnostic standard when cancer or dysplasia is suspected. Visual and tactile screenings remain foundational and should continue to be part of every comprehensive head and neck examination. 

But experienced clinicians also know that some lesions may appear deceptively benign while molecular changes are already occurring at the cellular level. That is where these newer tools may add value. 

Salivary genomic screening may help clinicians: 

• Identify lesions that may require expedited referral 

• Support monitoring decisions for persistent abnormalities 

• Improve patient understanding and case acceptance 

• Complement biopsy findings with additional molecular insight 

• Potentially reduce unnecessary invasive procedures in select cases 

It is also important to understand what these tests are not. They are not hereditary cancer risk assessments. They are not standalone diagnostic tools. They are not designed for indiscriminate use on every patient. These technologies function as adjunctive screening tools that complement comprehensive clinical evaluation, documentation, visual assessment, and referral protocols. 

The goal is not to test everyone for everything. The goal is to use the right tool at the right time, for the right patient, with the right clinical reasoning. Persistent lesions, unresolved ulcerations, clinically ambiguous tissue changes, higher-risk patients, and lesions being monitored over time may represent situations where additional genomic insight becomes valuable. And perhaps most importantly, these technologies may help us move away from relying too heavily on prolonged “wait and see” approaches before escalating care. 

Best practices in 2026 

As oral cancer detection evolves, best practices are evolving with it. The future of screening is not about replacing what clinicians already do well. It is about strengthening our ability to identify risk earlier, communicate more clearly, and make more informed decisions. 

Modern oral cancer detection increasingly includes three major components. First, comprehensive visual and tactile examination remains the foundation. A proper screening should include cervical lymph node evaluation, submandibular assessment, tongue mobility, floor of mouth palpation, and careful examination of high-risk tissue regions. Documentation, photography, and lesion tracking remain critical for continuity of care.⁶ 

Second, risk-based patient assessment matters more than ever. Clinicians should continue evaluating tobacco history, alcohol use, HPV exposure, immune status, inflammatory burden, age, lesion persistence, and systemic health factors. We also need to remember that younger patients with limited traditional risk factors are increasingly presenting with HPV-associated oral and oropharyngeal cancers.⁷ 

Third, salivary insights and genomic technologies are becoming part of a broader movement toward precision dentistry. Dentistry is moving toward more individualized, trackable, and predictive models of care. Saliva may help us evaluate inflammatory burden, microbial patterns, host-response markers, and genomic changes connected to disease progression. 

This is where dentistry becomes especially exciting. Technology is not replacing clinicians. It is giving clinicians more information to support earlier, better, and more confident decisions. 

As oral cancer detection continues to evolve, our responsibility evolves with it. The future may depend not only on what we can visually identify, but also on what we can detect molecularly before disease progression becomes clinically obvious. 

In the final installment of this series, we will explore how salivary technologies are beginning to provide trackable patient insights that can help identify patterns over time, support personalized and predictive care models, improve patient engagement, and potentially enable earlier disease diagnostics across dentistry and health care. 

Editor's note: This article appeared in the August/September 2026 print edition of RDH magazine. Dental hygienists in North America are eligible for a complimentary print subscription. Sign up here.

References 

1. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis. J Am Dent Assoc. 2008;139(7):896-905. 

2. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for oral cancer detection. Oral Oncol. 2008;44(1):10-22. 

3. Yakob M, Fuentes L, Wang MB, et al. Salivary biomarkers for detection of oral squamous cell carcinoma. Curr Oral Health Rep. 2014;1(2):73-83. 

4. Sahibzada HA, Khurshid Z, Khan RS, et al. Salivary IL-8, IL-6 and TNF-α as potential diagnostic biomarkers for oral cancer. Diagnostics. 2017;7(2):21. 

5. Perera M, Al-Hebshi NN, Speicher DJ, et al. Emerging role of bacteria in oral carcinogenesis. Crit Rev Microbiol. 2016;42(1):37-52. 

6. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52(4):195-215. 

7. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence. J Clin Oncol. 2011;29(32):4294-4301.